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characteristics may be one stable frequency in at least 1% 
of the population and, per se, may not be able to cause any 
genetic disease. These polymorphisms are responsible for the 
differences of the individual characteristics in each human 
being in our population.
Recently, the data base of the International HapMap Project 
was made available, presenting the so-called “tagSNPs” (SNPs 
that sign the presence of a specific set of alleles in other close 
polymorphisms). The polymorphisms located very close one 
to the other tend to segregate together from the parents to 
the children, forming haplotypes. The idea of the “tagSNPs” 
is to genotype only some polymorphisms representing 
these haplotypes and infers the others by probability. Each 
population has its own set of “tagSNPs”, contemplated in a 
large part by the HapMap Project2. 
Inherent to all the pharmacological treatments, there 
are situations of non-response and toxicity to usual doses 
of drugs, which can not be explained by comorbidities, 
specific physiological situation or patients’ habits. The 
pharmacogenetics is the knowledge field focused on the 
study of the genetic polymorphism interactions with the 
pharmacology, treating the changes in the drug’s kinetics 
(absorption, transport, metabolization and clearing), as well as 
on the dynamics of the drugs’ interaction with their receptors3.
The pharmacogenetics aims at early detecting individual 
characteristics of the patients that can identify them as “good 
respondents”, or “bad respondents”, to each pharmacological 
treatment. Millions of dollars are spent every year, all over 
the world, in non-effective treatments (unable to remove 
the patient from a risk situation), or with hospitalizations due 
to pharmacological intoxications; such situations could be 
prevented optimizing the “trial and error” practice used in 
clinic4. The data are really alarming: around 7% of the total 
hospitalizations in the United States in 2006 and 6.5% in the 
United Kingdom in 2004 were due to adverse reactions to 
medications5,6. These numbers show the great importance 
of the personalization and rationalization of medication use. 
Basically, the greatest objective of the pharmacogenetics 
is to individualize the pharmacological treatments in a 
rational, directed and, above all, with strong scientific basis 
way to reduce the side effects, the therapeutic inefficacy 
and their consequences.
The advances in molecular biology and biochemistry have 
been evidencing the actual challenge of the pharmacogenetics: 
each physiological pathway has dozens of proteins that interact 
among themselves; each protein, codified by its gene (with 
polymorphisms), can have its transcription regulated by 
Abstract
The pharmacogenetics is one of the most promising fields 
of medicine. The conclusion of the Genome Project allowed 
this field to start discovering complex factors modulating 
the response to drugs, and new technologies are close a 
great expansion of the area. The cardiovascular diseases are 
currently among the major causes of hospitalizations and 
death, and have been the target of a large part of genetic 
studies of complex diseases. Parallel to the susceptibility to 
disease markers identification, it is necessary to investigate 
how different genetic profiles can change the responses to the 
currently used drugs. The biological system that controls the 
endothelial production of the nitric oxide has been one of the 
greatest targets in the pharmacological responses to the drugs 
used in the cardiovascular diseases therapy. This review aims at 
approaching the current knowledge on interaction among the 
genetic variations of eNOS and the pharmacological responses 
to the drugs used in the cardiovascular system.
Introduction
The initial results of the Genome Project were published in 
20011 and, over these eight years, there was a great advance in 
the understanding of the molecular mechanisms that involve 
the genetic influences on the human being. One of the main 
implications of the accumulated human genome knowledge 
is the genetic characteristics investigation and its association 
to phenomena not explained so far. 
The variable genetic characteristics (polymorphisms) 
studied are divided into three large groups: single nucleotide 
polymorphisms - SNPs, variation in the specific sequences 
of repeats number (micro satellites and variable number of 
tandem repeats), and insertions/deletion of specific genic 
sequences. To be characterized as polymorphisms, these 
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several other proteins, whose genes also have polymorphisms. 
Adding complexity to the above, the biochemical pathways 
interact among themselves in complex ways (many of them 
still unknown) so sometimes the actual cause of a change in 
the response to the drug is not obvious at all.
Such complexity leads to two generic streams for the 
pharmacogenetics study: the studies based on Genome 
Wide Association Studies (GWAs), and the studies based on 
the physiological and physiopathological pathways of the 
biological systems.
Genome Wide Association Studies are large studies that 
use genotyping techniques in large scale, able to characterize 
thousands of polymorphisms all over the genome in a 
sole experiment. This kind of trial allows the generation of 
results without preconceived hypothesis. The idea behind 
the use of these studies in pharmacogenetics is that, many 
times, the response to drugs involves not known pathways 
yet, making difficult the generation of hypotheses a priori7. 
Thus, clinical studies in large scale are possible without 
the need of choosing previously polymorphism candidates 
for association with determined phenotype. GWAs have a 
huge potential of generating new hypotheses and, probably, 
they will be able to leverage the knowledge development 
of the pharmacogenetics4 in the medium term. However, 
there are severe limitations in this kind of study: the need 
of large number of patients or of a large clinical effect by 
these polymorphisms, for the study to have enough statistical 
power to detect significant differences. GWAs involve very 
high costs, around millions of dollars each8; in addition, the 
great efforts of patients’ recruitment (which do not tend to 
reduce the cost as the technologies used nowadays4) provide 
an indication that the GWAs are probably restricted to large 
centers, rich in financing7. 
By definition, GWAs test only the common variants of 
the genes, completely ignoring the rare variants (which can, 
potentially, exercise large effects in the response to drugs)9,10; 
in addition, the current chips are based on the HapMap 
Project panels for covering almost the totality of common 
SNPs in the genome, so the populations not represented in 
these panels can have errors in the haplotype inferences, due 
to the differences in the “tagSNPs”, not being included now in 
this kind of study11. There are also technical limitation in the 
studies by DNA chips. To have an idea, from 83 genic variants 
with great clinical importance studied by Peters7, only 45 are 
included in the HapMap Project panels due to the technical 
difficulties (making impossible to determine large insertions/
deletions), showing that this technology can be far from being 
a definitive tool for pharmacogenetical studiAnother challenge 
in the GWAs is the data interpretation; in some cases, there 
are relations that are clearly artifacts by statistical fluctuations8. 
So far, the majority of the GWAs was concentrated in the 
polymorphisms for susceptibility to diseases, existing only few 
studies in pharmacogenetics, so there are still a broad field 
for expanding this kind of study in the differentiated response 
to the drugs6.
There is another approach, maybe as efficient as the 
GWAs, for studying the genes that participate in already 
known physiological mechanism8. This vision is based on the 
suggestion that if a gene is implicated in a disease cause or 
is able to influence the response to a drug, probably other 
genes in the same pathway may be involved8. Ideally, previous 
studies determined the effect of the polymorphisms by 
molecular trials of expression and/or enzymatic activity, and 
the results found may then be checked in human beings, in 
clinical trials10. In these studies, the genotyping is performed 
by common methods, and is followed by the biochemical 
markers analysis related to the affected protein and by the 
association with the final phenotype (disease or response to 
the treatment). This final genotype-biochemical-phenotype 
approach is very valuable, because genetic polymorphisms 
can cause change in the protein activity or expressions. 
These, in turn, can change the plasmatic concentrations of 
some biochemical products involved in a physiopathological 
process. Thus, such polymorphisms can have a great 
predictive value in the medical clinic. Two recent examples 
of studies that can be mentioned are: i) polymorphisms in the 
synthase aldosterone gene study, with posterior concentration 
quantification of circulating aldosterone, and evaluation of the 
association with resistant hypertension12; ii) polymorphisms in 
eNOS study, quantification of the plasmatic levels of nitrite, 
and investigation of the association with pre-eclampsia13. 
This approach does not need so large human and financial 
resources and, due to its characteristics, it has a large potential 
of generating results more focused on the clinical problems, 
with applicability in the short term.
Probably, the ideal would be to search a GWAs 
complementation with traditional studies, connecting the 
broad reach of the GWAs with the advantages of being focused 
on great interest hypothesis. This combination could lead to 
more solid conclusions, without neglecting important findings7.
Ultimately, the pharmacogenetics is a new science, which 
promises large impacts on the way the diseases will be treated. 
This review will approach the interaction mechanisms of 
polymorphisms in the endothelial synthase gene of nitric oxide 
with the pharmacological responses to the cardiovascular 
drugs currently in use.
Relevance of the nitric oxide for the 
cardiovascular system
The endothelium has an important role in the vascular 
homeostasis regulation and the maintenance of the vascular 
energy, being involved with physiologial pathways important 
for the arterial resistance control to the blood flow. Among 
several mediators released by the endothelium, the nitric 
oxide (NO) plays a fundamental role in the regulation of the 
cardiovascular system. After its formation by the endothelium, 
the NO is spread to the smooth muscle and interacts with the 
heme group of soluble guanylate cyclase (sGC) making it active. 
This enzyme synthetizes the cyclic guanosine monophosphate 
(GMPc) from the guanosine triphosphate (GTP), leading to an 
accumulation of GMPc in these cells. This activates intracellular 
signing pathways that decrease the vascular smooth muscle 
contraction grade, leading to vessel relaxation14. In addition to 
these vascular effects, the NO is also involved in the inhibition 
of platelets aggregation and adhesion.
The NO is formed by of the NO-synthase enzymes 
(NOS), which catalyze the L-arginine in L-citrulline and NO. 
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There are three isoforms of this enzyme: neuronal (nNOS or 
NOSI), induced (iNOS or NOSII) and endothelial (eNOS or 
NOSIII)15. nNOS is found in a variety of cells that include the 
neurons and endothelial cells. Both, nNOS and eNOS, are 
contitutive isoforms and are calcium-dependent, needing an 
increase in the intracellular calcium levels and consequent 
binding with the calmodulin (CaM) for the activation of these 
enzymes. The iNOS is not contitutive and is expressed in 
inflammatory processes.
In the cardiovascular system, the eNOS is the main 
responsible for the NO synthesis14,16. eNOS is located in 
the invaginations of the plasmatic membrane of endothelial 
cells, denominated caveolae. The interaction of eNOS with 
a protein called caveolin results in the inactivity of eNOS, 
which may be, partially, by the occupation of the calmodulin 
binding site17. 
The reduction of the expression or activity of eNOS 
may result in lower production of NO. Several studies have 
suggested that the unbalance in the NO bioavailability plays a 
significant role in the endothelial dysfunction. Several diseases 
are associated to the endothelial dysfunction and bioavailabilty 
of NO, among them, hypertension18, pre-eclampsia19 and 
metabolic syndrome20.
The oxidative stress is involved in physiopathological 
processes of several cardiovascular diseases, and there are 
evidences that show its contribution to the endothelial 
dysfunction. The reactive oxygen species (ROS), such as the 
superoxide anion, react with NO resulting in the formation of 
peroxynitrile. The increase in the mild ROS production leads, 
therefore, to a reduction of the bioavailability of NO21, being 
able to favor the appearance of several cardiovascular diseases. 
The increase of the ROS can also lead to the oxidation of 
the BH4 cofactor of eNOS, leading to a decoupling of this 
enzyme. This way, the eNOS starts producing superoxide 
anion instead of NO22, leading to a vicious cycle that increase 
more and more the oxidative stress and reduces more and 
more the NO availability. 
Relevance of the nitric oxide for the 
responses to the cardiovascular action drugs
Several drug groups used in the treatment of cardiovascular 
diseases increase the bioavailability of NO. Among them, 
we have the Angiotensin converting enzyme inhibitors 
(ACEI), Angiotensin II receptors antagonists (Ang II) and the 
calcium channel blockers (CCB)23. In addition to these anti-
hypertensives, several studies have evidenced the increased 
NO caused by 3-methylglutaryl coenzyme A reductase 
inhibitors (statins), probably in a way independent from the 
lipid levels reduction24,25.
ACE inhibitors act reducing Ang II concentrations, a 
powerful endogenous vasoconstrictor. In parallel, there is an 
increase of the kinin concentrations (which prevailing effect is 
opposite to Ang II), and this contributes to the cardiovascular 
effect of these drugs26. The ACEI seems to stimulate the 
expression and activity of eNOS27,28, probably involving the 
kinins binding to their receptors29-31. These effects are inhibited 
by the concurrent treatment with HOE-140, an antagonist of 
B2 receptor of kinin
27,32. 
The inhibitors of Ang II receptors are used because they 
inhibit competitive Ang II binding to AT1 receptor, attenuating 
the vasoconstrictor effects of Ang II. These drugs also act 
increasing the bioavailability of NO, probably due to the 
increase of the eNOS protein expression or activation of other 
receptors that lead to eNOS activation23,33.
The calcium channels blockers (CCB) inhibit the calcium 
entry into the smooth muscle cells, and then lead to a lower 
contractility and cardiac output. There are evidences that 
this class also increases the bioavailability of NO23,34. Clinical 
studies showed evidences of significant improvement of 
endothelium-dependent vasodilatation in hypertensive and 
hypercholesterolemic patients treated with CCB, showing the 
reversion of endothelium dysfunction23. Probably, the increase 
of NO derives from the increased activity and expression of 
eNOS associated to these drugs35.
The statins are among the most broadly used and effective 
drugs for preventing cardiovascular diseases36, specially when 
their action on the circulating concentration of lipoproteins 
and their long term cardioprotector effects are taken into 
consideration. Some of the pleiotropic effect observed seems 
to be associated to the increase of the endogenous production 
of NO37,38, possibly attributed to the increased expression and 
activity of eNOS39,40.The erectile dysfunction is a disorder 
with neuronal and vascular origin and has been considered 
as an early risk factor for other cardiovascular diseases41. The 
phosphodiesterase 5 inhibitors (PDEI-5) are drugs used in 
the erectile dysfunciton and in the pulmonary hypertension 
as they act by means of the GMPc degradation inhibition, 
leading to a relaxation of the vessel smooth muscles. In case 
of pulmonary hypertension, this would lead to a normalization 
of the pressure, and in the erectile dysfunction, it would make 
easy the penis tumescence from the neurogenic stimulation41. 
Syndromes where the NO synthesis is damaged, such as 
diabetes and heart failure, reduce the efficacy of the current 
PDEI-5 in inducing the vasodilatation42,43 and change the 
cardiac function44. 
eNOS genetic polymorphisms
The eNOS gene (located in the 7q35-7q36 region) contains 
26 exons, 25 introns and approximately 21 to 22 Kb45,46. Since 
its characterization in the beginning of the 1990’s, a large 
number of polymorphic sites was identified, including VNTRs, 
dinucleotides repeats (CA)n and SNPs47. Several of these 
polymorphisms have been associated to cardiovascular diseases, 
such as hypertension, pre-eclampsia, among others47-49.
One of the most studied clinically relevant polymorphisms 
is a SNP in the promoter region (T-786C), frequently associated 
to the development of coronary disease50,51. In vitro studies 
indicate that the thymin replacement by cytosine in the position 
-786 reduces by around 50% the transcriptional activity51,52 (fig. 
1A and 1B). Probably, this effect occurs due to a higher binding 
of RPA1 (replication protein A1), which acts as a genic repressor 
protein51 in individuals with the rare alelo (fig. 1B).
Another broadly studied polymorphism in the eNOS gene 
is a VNTR located in intron 4 (27 pb repeat). The mostly 
found alelos present four copies (variant a, rarer) or five copies 
(variant b, more common), The functionality and association 
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studies of this polymorphism with cardiovascular events have 
demonstrated conflicting results47,53,54. Recently, it has been 
proposed that this polymorphism would regularize the eNOS 
expression by the formation of small RNAs (sirRNA). Endothelial 
cells containing five copies present higher quantities of sirRNA 
and lower levels of mRNa of eNOS than the cells containing four 
copies55,56 (fig. 1C and 1D), which could explain the association 
of this polymorphism with cardiovascular risk.
A third polymorphism, a SNP localized in exon 7 of 
eNOS gene has been associated to cardiovascular risk47,57. 
This polymorphism is characterized by a guanine conversion 
by thymin in pósition 894 of the gene, and consequent 
replacement of glutamine (most common alelo) by aspartate 
(rarest alelo) in residue 298 of eNOS (Glu298Asp)45. Evidences 
point out to smaller NO formations in individuals holding Asp 
alelo, leading to possible functional changes58,59. Endothelial 
cells holding this alelo seem to produce less NO by a decrease 
in the availability of eNOS in the caveolae of these cells60 (fig. 
1E and 1F). The cellular location of eNOS and its binding to 
caveoline 1 play a fundamental role for the enzyme activity. 
Despite the previously discussed evidences, there is a 
certain controversy in the genetic influence of eNOS on the 
cardiovascular diseases47. A possible explanation for these 
discrepant results can be that the simple clinical associations 
performed from the analysis of a single genetic marker 
(genotype) with a clinical phenotype do not have enough 
power to detect its small effects. An alternative approach would 
be an analysis of the combination of several genetic markers in 
parallel (haplotype)48,61. For example, Sandrim et al62 evaluated 
the influence of genotypes/haloptypes of eNOS in the 
increase of the blood pressure using the three most common 
polymorphisms (T-786C; Glu298Asp and 4b/a). The genotype 
analysis did not evidence that there are significant differences 
between normotensives and hypertensives. However, the 
haplotypic analysis clearly showed the existence of significant 
differences between the two experimental groups. Also, other 
studies showed the association of haplotypes of eNOS with 
different circulating concentrations of nitrite, which suggests 
that these haplotypes can have functional implications that 
provide varied risk of cardiovascular diseases development63,64. 
This haplotypical approach seems to be more promising than 
the analysis of only a polymorphism at a time, specially in the 
study of complex diseases. 
Studies of the responses to drugs of 
cardiovascular action, being affected by 
eNOS polymorphisms
The studies have been showing relations between 
polymorphisms of the eNOS gene with differentiated 
Figure 1 - Representation of possible mechanisms explaining the associations of polymorphisms in the nitric oxide endothelial synthase gene (eNOS) with variations 
of its action. A and B: polymorphism in the promoter region (T-786C); C and D: polymorphism in intron 4 (4b/a); E and F: polymorphism in exon 7 (Glu298Asp). RPA1 
(Replication Protein A1), MP (Plasmatic Membrane), CAV 1 (Caveolin 1) and sir-RNA (short intronic repeat RNA). Refer to the text for details.
CAVEOLA
ACTIVATORS
CAVEOLA
ACTIVATORS
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responses to several classes of drugs used in the treatment of 
cardiovascular diseases.
Recent evidences suggest a modulation of statin effects 
by genetic polymorphisms of eNOS. Curiously, a study with 
endothelial cells ion culture, treated with statins, showed 
that these drugs induce high increases of the mRNA levels 
of eNOS in endothelial cells with CC genotype, when 
compared to TT cells for the T-786C polymorphism65. This is 
due, probably, to the higher transcriptional activity, increase of 
mRNA stability and decrease of RPA1 expression65. Confirming 
these findings in cultures of endothelial cells, a clinical study 
showed similar effects with atorvastatin66. In this study, it was 
demonstrated that the treatment with statin increased the 
bioavailabilty of NO and decreased the oxidative stress only 
in CC homozigous individuals for the T-786C polymorphism66. 
Note that healthy individuals were studied, making the drug 
have much less chance of producing significant effects66. 
Later, it was observed that the anti-inflammatory effects of 
the atorvastatin are modulated by the same polymorphism, 
leading to a significant reduction in the inflammatory cytosine 
concentrations (CD40L, VCAM-1, P-selectin and MMP-9) in 
individuals with CC genotype, but not in the TT individuals67. 
Functional studies demonstrated subsequently that the short 
term treatment with statins is able to reduce the fluidity of 
the plasmatic membrane of red blood cells in individuals 
with CC genotype, but not with the TT genotype, during the 
treatment with atorvastatin68. Together, these findings indicate 
that the atorvastatin could be more useful for the prevention 
of cardiovascular events in individuals with the CC genotype 
(which cardiovascular risk has been showed increased) than 
in individuals with TT genotype.In any way, the study results 
with atorvastatin mentioned may be interpreted cautiously, 
because there were not evaluated clinically relevant events 
and the simple measurement of the biochemical markers can 
not be effective to indicate new drug uses. Clinical studies 
focusing clinically relevant events may be performed to prove 
the previously discussed results.
While the majority of the pharmacogenetic studies of the 
statins related to eNOS are centered in the polymorphism in 
the promoter region of eNOS, the polymorphism in intro 4 
also seems to modulate the response to the statins. Kunnas et 
al69 evaluated the coronary vasodilation induced by adenosin 
in healthy individuals after six months of treatment with 
pravastatin. The individuals holding the “a” alelo showed 
significant improvement of vasodilation when compared to 
the individuals with “bb” genotype, possibly by the higher 
increase if the endothelial production of NO in individuals 
with rare alelo69.
Other polymorphism in the eNOS gene, Glu298Asp in 
exon 7, seems to modulate the estradiol effects in the platelet 
function. The pre-treatment with 17β-estradiol increased 
in a significant way the platelet aggregation rate, together 
with the increased release of superoxide ions by platelet 
only in homozigous individuals for the Asp298 alelo. The 
release of NO derived from the platelets was not changed 
by the Glu298Asp, T-786C and 4b/a polymorphisms after the 
treatment. Additionally, the hormone effect on the platelet 
function was not affected by the polymorphisms in the 
promoter region and intron 458. 
One of the most important drug classes on the hypertensive 
control, specially in the case of excessive volume, is the 
thiazide diuretics. The hydrochlorothiazide (HCTZ) is 
its most used representative in the medical clinic. It was 
demonstrated that the Glu298Asp polymorphism in the 
eNOS gene is able to modulate the response to HCTZ, so the 
homozigous individuals for the Glu alelo have a reduction 
in the blood pressure levels significantly higher than the 
individuals holding the alelo Asp70. Although the significant 
effect, it is small, which shows evidence that it is difficult a 
single polymorphism to be able to explain all the genetic 
background behind the variations in the pharmacological 
responses of a medication class.
Other anti-hypertensive classes of great importance are the 
betablockers and the AT-1 receptor inhibitors of angiotensin 2. 
A study using techniques analog to GWAs showed promising 
results associating less studied polymorphisms of eNOS to 
variations in the pharmacological responses of propanolol 
and irbesartan (betablocker and AT-1 receptor inhibitor of 
angiotensin 2, respectively). Alelo G of A2996G polymorphism 
was associated to a higher decrease of the blood pressure 
from the atenolol betablocker effect in relation to alelo A71. 
Alelo A of the G498A polymorphism was associated to a better 
response before betablocker and irbersartan71. The presence 
of the 2996G alelos and 498A alelo could provide a higher 
benefit for the holders of these alelos treated with these anti-
hypertensives. These results, although promising, may have 
to be confirmed in studies with a higher number of patients 
from different populations. 
The hypertension usually is treated with the addition of 
different classes of anti-hypertensives until the blood pressure 
decreases to the preconized levels72. Hypertensive resistant 
are the individuals who keep their blood pressure levels 
above 140/90 mmHg despite the use of three different classes 
of anti-hypertensives, including a diuretic. In this context, 
it was demonstrated a non significant trend of association 
between the Asp alelo (Glu298Asp) and hypertension 
resistant73. Later studies analyzing the haplotypes of eNOS 
did not confirmed any association with the resistance to the 
anti-hypertensive therapy62.
The NO availability affects the bias to erectile dysfunction 
similarly to the hypertension. The drug classes used in the 
erectile dysfunction treatment, the PEI-5. is also influenced by 
the polymorphisms in its therapeutical response. As previously 
commented, NO availability is a determining factor for the 
PDEI-542 activity. It was demonstrated that the homozigous 
men for Asp alelo (associated to a lower production on NO) 
obtained lower response to sildenafil when compared to 
individuals with genotype Glu/Glu74.
General conclusions
The pharmacogenetics is a very recent pharmacology 
area, and it still has to grow. The genome project results 
caused the promotion and the popularization of the area, 
and we are living presently a moment close to a large 
expansion, thanks to the Genome Wide Association Studies. 
After that, the majority of the studies still focus on the 
genetic base of complex diseases, without great attention 
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to the pharmacological responses. In relation to the nitric 
oxide production systems, important initial steps were taken, 
and today there are strong evidences that the statins and 
estradiol in fact can experience modulation by the genetic 
background of the eNOS gene in their pharmacological 
functions. Deeper studies are still necessary in relation to 
anti-hypertensives, and other medications that act on the 
cardiovascular system.
It is important to emphasize that the advances promised 
by the pharmacogenetics unfortunately, are still far from the 
clinical practice and of the patient.
Outlook
The future of the medicine goes more and more to the 
personalization of the therapies and for the national use 
of the pharmacological treatments. The pharmacogenetics 
has a great role in this hypothetic scenario. The idea led to 
an utopic extreme, would be to identify the major genetic 
polymorphisms at the birth, in order to choose, a priori, all the 
possible treatments of the individual, adequating the doses to 
the metabolic profile predicted by the DNA.
The hypertension, one of the worse diseases of the modern 
world, could be treated more effectively, even prevented, 
by means of the early identification of risk markers, and 
prophylactic treatment.
In general, the genetic advances promise to revolutionize 
the medicine in the next decades; it is necessary to evaluate 
which of the great promises of the end of the 20th century 
(genic therapy, stem cells, pharmacogenetics) will really 
succeed, and in which proportion.
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